Hong Qin, Wenhua Li, Meifeng Xu, Keqian Zhang, Xianquan Zhang, Zhihua Ruan
Department of Oncology, Southwest Hospital, The Third Military Medical University, Chongqing, China (mainland)
Med Sci Rev 2016; 3:55-63
The purpose of the present meta-analysis was to evaluate the effectiveness of immunotherapy for patients with advanced non-small cell lung cancer (NSCLC).
MATERIAL AND METHODS: We searched PubMed, EMBASE, and Cochrane Library databases, and finally 18 randomized controlled trials (RCT) were selected for analysis. The meta-analysis was performed using Stata11.0 software.
RESULTS: In total, 18 RCTs involving 4554 participants were included in the meta-analysis. The results indicated that the RR (response rate), DCR (disease control rate), overall survival (OS), PFS (progression-free survival) (p=0.002, p=0.001, p=0.024, p=0.002, respectively), and part of T lymphocyte surface antigens (CD4+ and NK+) (p=0.000, p=0.000) were significantly improved when treated with immunotherapy. However, the change of CD3+ and CD8+ between immunotherapy and control group was not significantly different.
CONCLUSIONS: Patients with advanced NSCLC who are treated with immunotherapy achieve a higher response rate and longer survival.
Keywords: Carcinoma, Non-Small-Cell Lung, Immunotherapy, Active, Meta-Analysis as Topic, review